<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="psb1843-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float">
 <label>Table 1</label>
 <caption>
  <p>Drugs under investigation for the treatment of COVID‐19
   <sup>29,32</sup>
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <col align="left" span="1"/>
  <col align="left" char="×" span="1"/>
  <col align="left" char="×" span="1"/>
  <thead valign="bottom">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="bottom" rowspan="1" colspan="1">Candidate</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Possible mechanism(s) of action</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Development status</th>
   </tr>
  </thead>
  <tbody valign="top">
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Chloroquine or hydroxychloroquine</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>• Impairs virus release after cell entry</p>
     <p>• Impairs virus binding to cell receptor</p>
     <p>• Modulates immune response</p>
     <p>• Hydroxychloroquine is associated with fewer adverse effects than chloroquine</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Given FDA Emergency Use Authorisation in the USA, but the MHRA states it should only be used within a clinical trial. Being investigated in the WHO SOLIDARITY trial</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Hydroxychloroquine + azithromycin</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>• Hydroxychloroquine as above</p>
     <p>• Azithromycin – possible antiviral activity and prevention of secondary bacterial infection</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">One trial suggests reduction in viral nasopharyngeal carriage at 6 days in 20 patients compared with unmatched untreated cohort, with azithromycin reinforcing the effect of hydroxychloroquine
     <xref rid="psb1843-bib-0034" ref-type="ref">
      <sup>34</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Lopinavir/ritonavir</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>• Viral protease inhibitors</p>
     <p>• May inhibit SARS virus and reduce adverse outcomes of infection</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Randomised trial (n=200) suggested no benefit.
     <xref rid="psb1843-bib-0036" ref-type="ref">
      <sup>36</sup>
     </xref> Trial now underway in combination with steroids. Being investigated in the WHO SOLIDARITY trial
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Interferon beta‐1a</td>
    <td align="left" valign="top" rowspan="1" colspan="1">• May counter suppression of interferon beta by SARS‐CoV‐2</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Administered by inhalation; trial underway to determine impact on severity of complications</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Remdesivir</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>• Blocks viral RNA synthesis</p>
     <p>• Broad‐spectrum activity against coronaviruses</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Given Emergency Use Authorisation in the USA; EMA rolling review underway. Clinical trials now reporting preliminary results;
     <xref rid="psb1843-bib-0038" ref-type="ref">
      <sup>38</sup>
     </xref>, 
     <xref rid="psb1843-bib-0039" ref-type="ref">
      <sup>39</sup>
     </xref> ACTT trial indicates beneficial effect on time to recovery. One of the drugs in the WHO SOLIDARITY trial
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Tocilizumab</td>
    <td align="left" valign="top" rowspan="1" colspan="1">• Blocks interleukin‐6 signalling, which may counter cytokine release syndrome in severe COVID‐19</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Trial supported by US FDA underway (COVACTA) in patients with severe COVID‐19 pneumonia</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Favipiravir + interferon alpha</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>• Blocks viral RNA synthesis</p>
     <p>• Stimulates innate antiviral response</p>
    </td>
    <td rowspan="2" align="left" valign="top" colspan="1">Trials underway in China</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Favipiravir + baloxavir marboxil</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>• Blocks viral RNA synthesis</p>
     <p>• Baloxavir licensed in USA for flu</p>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Favipiravir 
     <italic>vs</italic> umifenovir
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>• Blocks viral RNA synthesis</p>
     <p>• Blocks virus‐cell fusion</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">In an unreviewed randomised non‐blinded trial (n=240), clinical recovery rates at 7 days were similar for favipiravir and umifenovir.
     <xref rid="psb1843-bib-0040" ref-type="ref">
      <sup>40</sup>
     </xref> Trials of favipiravir underway in India
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Ribavirin + interferon alpha, lopinavir/ritonavir + interferon alpha, and ribavirin + lopinavir/ritonavir + interferon alpha</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>• Ribavirin may reduce viral replication</p>
     <p>• Triple therapy recommended by National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of novel coronavirus pneumonia (Trial Version 5) 2020</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Trials underway in China
     <xref rid="psb1843-bib-0041" ref-type="ref">
      <sup>41</sup>
     </xref>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
